Fox News: RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer

[riky]

RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
     

- RECORD-1 trial shows RAD001 reduces risk of disease progression by 70%
- RAD001 is first and only drug to show significant benefit after failure of approved therapies Sutent(R) or Nexavar(R),** with potential to address unmet medical need
- Once-daily oral RAD001 directly targets and continuously inhibits mTOR, a protein that controls tumor cell division and blood vessel growth
- RAD001 is currently being studied in multiple types of cancer including neuroendocrine, breast, gastric, lung, and lymphoma<img src="You are not allowed to view links. Register or Login" height="1" width="1"/><img src="You are not allowed to view links. Register or Login" height="1" width="1"/>
     

You are not allowed to view links. Register or Login